A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2009
At a glance
- Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors PharmAthene
- 28 Apr 2009 Results were presented at the 12th Annual Conference on Vaccine Research, according to a PharmAthene media release.
- 24 Feb 2009 Results were presented at the 7th Annual ASM Biodefence meeting, according to a PharmAthene media release.
- 14 Sep 2008 Actual patient number (415) added as reported by ClinicalTrials.gov.